Asunaprevir/Daclatasvir/Beclabuvir Fixed-Dose Combination Safety Surveillance in Japanese Patients With Chronic Hepatitis C (HCV) or Japanese Patients With Compensated Cirrhosis
Phase of Trial: Phase IV
Latest Information Update: 12 Jul 2018
At a glance
- Drugs Asunaprevir/becabluvir/daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 02 Jul 2018 Planned End Date changed from 20 Nov 2019 to 14 Nov 2019.
- 02 Jul 2018 Planned primary completion date changed from 20 Nov 2019 to 14 Nov 2019.
- 09 Mar 2017 New trial record